Itolizumab (EQ001)
Acute Graft-Versus-Host Disease (aGVHD)
Key Facts
About Equillium
Equillium is pioneering immunobiology-based treatments for severe autoimmune and inflammatory conditions through two distinct technology platforms. Its lead asset, itolizumab (EQ001), is in multiple Phase 1b trials for acute GVHD, systemic lupus erythematosus, and lupus nephritis, while its novel AhR modulator, EQ504, represents a non-immunosuppressive approach to tissue repair and inflammation. The company's strategy centers on modulating key immune pathways to address diseases with significant unmet need, positioning itself as a leader in next-generation immunomodulation.
View full company profileAbout Equillium
Equillium is pioneering immunobiology-based treatments for severe autoimmune and inflammatory conditions through two distinct technology platforms. Its lead asset, itolizumab (EQ001), is in multiple Phase 1b trials for acute GVHD, systemic lupus erythematosus, and lupus nephritis, while its novel AhR modulator, EQ504, represents a non-immunosuppressive approach to tissue repair and inflammation. The company's strategy centers on modulating key immune pathways to address diseases with significant unmet need, positioning itself as a leader in next-generation immunomodulation.
View full company profileAbout Equillium
Equillium is pioneering immunobiology-based treatments for severe autoimmune and inflammatory conditions through two distinct technology platforms. Its lead asset, itolizumab (EQ001), is in multiple Phase 1b trials for acute GVHD, systemic lupus erythematosus, and lupus nephritis, while its novel AhR modulator, EQ504, represents a non-immunosuppressive approach to tissue repair and inflammation. The company's strategy centers on modulating key immune pathways to address diseases with significant unmet need, positioning itself as a leader in next-generation immunomodulation.
View full company profile